An observational study in Acute Pancreatitis and Pancreatitis, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-25.
Sponsored by University Hospital, Basel, Switzerland · Observational
The purpose of this study is to investigate if there is an association between copeptin level in serum and the severity of pancreatitis and if copeptin can be used as a predictor for organ failure and pancreatic necrosis with or without superinfection.
Acute pancreatitis may range from mild to severe disease with high mortality in case of infected pancreatic necrosis. Due to its rising incidence it remains an important healthcare problem in Europe and US. The assessment of the severity of pancreatitis is crucial for the further management and the prognosis. Several quite complex scores like Ranson or APACHE II scores has been used in the past with reasonable sensitivity for necrosis or superinfection as well as inflammation markers like c-reactive Protein.
Copeptin, the C-terminal part of antidiuretic hormone, is a relatively stable peptide in blood circulation. Several studies investigated Copeptin in the presence of Systemic Inflammatory Response Syndrome (SIRS) or sepsis, myocardial infarction, lower respiratory tract infection and cerebral stroke. Copeptin has shown to be a helpful prognostic marker in these diseases. The aim of this prospective study is to investigate whether Copeptin can be used to assess the severity of pancreatitis.
752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.
This study's enrollment of 150 is below the median of 180 across 277 observational studies indexed under Pancreatitis.
Browse Pancreatitis studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients presenting to the emergency departement or in-hospital patients with acute pancreatitis
Exclusion Criteria:
Other: No intervention
No intervention
Association between copeptin level and severity of pancreatitis (according to Atlanta classification)
Copeptin level will be measured on admission into hospital and severity of pancreatitis will be classified according to the Atlanta criteria.
Time frame: 48 hours
Comparison of copeptin with C reactive protein and procalcitonin in terms of assessing severity of pancreatitis
Time frame: 48 hours
Predictive accuracy of copeptin, C reactive Protein (CRP) and procalcitonin in terms of developing organ failure, necrosis and/or superinfection and mortality
Determinating Atlanta score, Sofa score. Assessing local complications by checking CT scan and searching for superinfection in fine needle aspiration and/or biopsy.
Time frame: Duration of hospitalisation
Determine whether change in copeptin level from day 0 to 2 is associated with organ failure, necrosis and/or superinfection
To determine if the change in copeptin level is associated with organ failure, necrosis and superinfection
Time frame: Duration of hospitalisation
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland